Literature DB >> 2837320

Radioprotection of cells in culture by WR-2721 and derivatives: form of the drug responsible for protection.

G D Smoluk1, R C Fahey, P M Calabro-Jones, J A Aguilera, J F Ward.   

Abstract

Studies of V79-171 cells were undertaken to determine what extracellular or intracellular derivative of the drug WR-2721 is associated with radioprotection. The effect of preincubation at 23 +/- 1 degree C with WR-2721, and with derivatives of WR-2721 produced in medium containing alkaline phosphatase, upon survival of cells following subsequent gamma-irradiation was examined. It was established that WR-2721, WR-1065, WR-33278, WRSSCys, and other disulfide forms produced by reactions of WR-1065 with the medium do not provide significant protection when present only extracellularly. Protection was found to correlate with cellular levels of the thiol form of the drug (WR-1065) but not with the cellular level of the disulfide forms of WR-1065. Similar results were obtained with HeLa, Me-180, Ovary 2008, HT-29/SP-1d, and Colo 395 cell lines showing that human tumor cell lines behave in the same fashion as the V79-171 nontumorigenic hamster diploid cell line. None of the drug forms produced significant cytotoxicity under the conditions used. It was concluded that it is the cellular level of WR-1065 at the time of irradiation which determines protection. The results are consistent with protection mechanisms involving scavenging of hydroxyl radicals, hydrogen atom transfer to DNA radicals, depletion of oxygen near DNA, enhancement of rapid biochemical repair processes, or some combination of these mechanisms.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837320

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  20 in total

1.  Amifostine induces antioxidant enzymatic activities in normal tissues and a transplantable tumor that can affect radiation response.

Authors:  David J Grdina; Jeffrey S Murley; Yasushi Kataoka; Kenneth L Baker; Rangesh Kunnavakkam; Mitchell C Coleman; Douglas R Spitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-03-01       Impact factor: 7.038

2.  Induction of cellular antioxidant defense by amifostine improves ventilator-induced lung injury.

Authors:  Panfeng Fu; Jeffrey S Murley; David J Grdina; Anna A Birukova; Konstantin G Birukov
Journal:  Crit Care Med       Date:  2011-12       Impact factor: 7.598

Review 3.  Clinical and preclinical modulation of chemotherapy-induced toxicity in patients with cancer.

Authors:  K Hoekman; W J van der Vijgh; J B Vermorken
Journal:  Drugs       Date:  1999-02       Impact factor: 9.546

4.  Cancer Incidence in C3H Mice Protected from Lethal Total-Body Radiation after Amifostine.

Authors:  John A Cook; Sarwat Naz; Miriam R Anver; Anastasia L Sowers; Kristin Fabre; Murali C Krishna; James B Mitchell
Journal:  Radiat Res       Date:  2018-03-12       Impact factor: 2.841

5.  The cytoprotective drug amifostine modifies both expression and activity of the pro-angiogenic factor VEGF-A.

Authors:  S Dedieu; X Canron; H R Rezvani; M Bouchecareilh; F Mazurier; R Sinisi; M Zanda; M Moenner; A Bikfalvi; S North
Journal:  BMC Med       Date:  2010-03-24       Impact factor: 8.775

6.  Agents capable of eliminating reactive oxygen species. Catalase, WR-2721, or Cu(II)2(3,5-DIPS)4 decrease experimental colitis.

Authors:  A Keshavarzian; J Haydek; R Zabihi; M Doria; M D'Astice; J R Sorenson
Journal:  Dig Dis Sci       Date:  1992-12       Impact factor: 3.199

7.  Relationship between phosphorylated histone H2AX formation and cell survival in human microvascular endothelial cells (HMEC) as a function of ionizing radiation exposure in the presence or absence of thiol-containing drugs.

Authors:  Yasushi Kataoka; Jeffrey S Murley; Kenneth L Baker; David J Grdina
Journal:  Radiat Res       Date:  2007-07       Impact factor: 2.841

8.  Effect of amifostine (Ethyol) on the development of extraembryonic blood vessels in chick embryos.

Authors:  J Höper; A Hanjalic; R Sauer; L Plasswilm
Journal:  Strahlenther Onkol       Date:  1999-01       Impact factor: 3.621

9.  Experimental basis for increasing the therapeutic index of carboplatin in brain tumor therapy by pretreatment with WR compounds.

Authors:  F Doz; M E Berens; D R Spencer; D V Dougherty; M L Rosenblum
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

10.  Modulation of bleomycin-induced mitotic recombination in yeast by the aminothiols cysteamine and WR-1065.

Authors:  G R Hoffmann; J L Quaranta; R A Shorter; L G Littlefield
Journal:  Mol Gen Genet       Date:  1995-12-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.